Decreased sirtuin 1 in type 2 diabetes patients with abnormal BMD
IntroductionSirtuin 1, a class III histone deacetylase, plays a critical role in the pathophysiology of both diabetes mellitus and bone metabolism by promoting osteoblast differentiation and inhibiting osteoclast maturation. However, its exact impact on bone mineral density (BMD) and bone metabolism...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1480847/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582933613903872 |
|---|---|
| author | Yao Xu Tianxiao Hu Peiwu Jiang Xiujing Wang Jiaqi Yao Huiling Shen Zhenying Zhang Bojing Zheng Ting Wang Yanxia Ren Jing Wang Qingying Tan |
| author_facet | Yao Xu Tianxiao Hu Peiwu Jiang Xiujing Wang Jiaqi Yao Huiling Shen Zhenying Zhang Bojing Zheng Ting Wang Yanxia Ren Jing Wang Qingying Tan |
| author_sort | Yao Xu |
| collection | DOAJ |
| description | IntroductionSirtuin 1, a class III histone deacetylase, plays a critical role in the pathophysiology of both diabetes mellitus and bone metabolism by promoting osteoblast differentiation and inhibiting osteoclast maturation. However, its exact impact on bone mineral density (BMD) and bone metabolism in type 2 diabetes mellitus (T2DM) remains unclear. This study investigates the relationship between Sirtuin 1 levels, BMD, and bone metabolism in newly diagnosed T2DM patients, specifically examining alterations in Sirtuin 1 levels in those with concomitant osteoporosis or osteopenia.MethodsA total of 69 newly diagnosed T2DM patients and 82 control subjects with normal glucose tolerance (NGT) were enrolled. Serum Sirtuin 1 levels and bone turnover markers, including osteocalcin (OC), procollagen type 1 N-terminal propeptide (P1NP), and β-C-terminal telopeptide of type I collagen (β-CTX), were measured using enzyme-linked immunosorbent assay (ELISA). BMD was assessed via dual-energy X-ray absorptiometry (DXA). Comparisons of these parameters were made between the T2DM and NGT groups.ResultsT2DM patients were further categorized into a normal BMD group (DMn) and an osteopenia or osteoporosis group (DMo), and differences in Sirtuin 1 levels between these subgroups were analyzed. Risk factors for osteoporosis/osteopenia in T2DM patients were also evaluated. Serum Sirtuin 1 levels were found to be significantly diminished in the T2DM group relative to the control group (P < 0.05), with no significant differences in lumbar spine BMD, OC, 25(OH)D, and β-CTX between groups (P > 0.05). Osteoporosis incidence was higher in T2DM subjects compared to controls (34.8% vs. 18.3%, P = 0.026). Subgroup analysis revealed that SIRT1 levels in T2DM patients with osteoporosis or osteopenia exhibited a significant reduction compared to those with normal BMD (P < 0.05). Logistic regression indicated that Sirtuin 1, age, HDL-C, P1NP, and β-CTX were independent risk factors for osteoporosis in T2DM patients.DiscussionIn conclusion, decreased serum Sirtuin 1 levels are associated with bone turnover markers in T2DM patients and may serve as an independent risk factor and potential biomarker for diagnosing bone metabolism disorders in newly diagnosed T2DM patients. |
| format | Article |
| id | doaj-art-27bcc0e5291849c8b8e7827ce67fc685 |
| institution | Kabale University |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-27bcc0e5291849c8b8e7827ce67fc6852025-01-29T05:21:18ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-01-011510.3389/fendo.2024.14808471480847Decreased sirtuin 1 in type 2 diabetes patients with abnormal BMDYao Xu0Tianxiao Hu1Peiwu Jiang2Xiujing Wang3Jiaqi Yao4Huiling Shen5Zhenying Zhang6Bojing Zheng7Ting Wang8Yanxia Ren9Jing Wang10Qingying Tan11Department of Endocrinology, No.903 Hospital of PLA Joint Logistic Support Force, Hangzhou, ChinaDepartment of Endocrinology, No.903 Hospital of PLA Joint Logistic Support Force, Hangzhou, ChinaDepartment of Vascular Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, ChinaDepartment of Endocrinology, No.903 Hospital of PLA Joint Logistic Support Force, Hangzhou, ChinaDepartment of Endocrinology, No.903 Hospital of PLA Joint Logistic Support Force, Hangzhou, ChinaDepartment of Endocrinology, No.903 Hospital of PLA Joint Logistic Support Force, Hangzhou, ChinaDepartment of Endocrinology, No.903 Hospital of PLA Joint Logistic Support Force, Hangzhou, ChinaDepartment of Endocrinology, No.903 Hospital of PLA Joint Logistic Support Force, Hangzhou, ChinaDepartment of Endocrinology, No.903 Hospital of PLA Joint Logistic Support Force, Hangzhou, ChinaDepartment of Endocrinology, No.903 Hospital of PLA Joint Logistic Support Force, Hangzhou, ChinaDepartment of Endocrinology, No.903 Hospital of PLA Joint Logistic Support Force, Hangzhou, ChinaDepartment of Endocrinology, No.903 Hospital of PLA Joint Logistic Support Force, Hangzhou, ChinaIntroductionSirtuin 1, a class III histone deacetylase, plays a critical role in the pathophysiology of both diabetes mellitus and bone metabolism by promoting osteoblast differentiation and inhibiting osteoclast maturation. However, its exact impact on bone mineral density (BMD) and bone metabolism in type 2 diabetes mellitus (T2DM) remains unclear. This study investigates the relationship between Sirtuin 1 levels, BMD, and bone metabolism in newly diagnosed T2DM patients, specifically examining alterations in Sirtuin 1 levels in those with concomitant osteoporosis or osteopenia.MethodsA total of 69 newly diagnosed T2DM patients and 82 control subjects with normal glucose tolerance (NGT) were enrolled. Serum Sirtuin 1 levels and bone turnover markers, including osteocalcin (OC), procollagen type 1 N-terminal propeptide (P1NP), and β-C-terminal telopeptide of type I collagen (β-CTX), were measured using enzyme-linked immunosorbent assay (ELISA). BMD was assessed via dual-energy X-ray absorptiometry (DXA). Comparisons of these parameters were made between the T2DM and NGT groups.ResultsT2DM patients were further categorized into a normal BMD group (DMn) and an osteopenia or osteoporosis group (DMo), and differences in Sirtuin 1 levels between these subgroups were analyzed. Risk factors for osteoporosis/osteopenia in T2DM patients were also evaluated. Serum Sirtuin 1 levels were found to be significantly diminished in the T2DM group relative to the control group (P < 0.05), with no significant differences in lumbar spine BMD, OC, 25(OH)D, and β-CTX between groups (P > 0.05). Osteoporosis incidence was higher in T2DM subjects compared to controls (34.8% vs. 18.3%, P = 0.026). Subgroup analysis revealed that SIRT1 levels in T2DM patients with osteoporosis or osteopenia exhibited a significant reduction compared to those with normal BMD (P < 0.05). Logistic regression indicated that Sirtuin 1, age, HDL-C, P1NP, and β-CTX were independent risk factors for osteoporosis in T2DM patients.DiscussionIn conclusion, decreased serum Sirtuin 1 levels are associated with bone turnover markers in T2DM patients and may serve as an independent risk factor and potential biomarker for diagnosing bone metabolism disorders in newly diagnosed T2DM patients.https://www.frontiersin.org/articles/10.3389/fendo.2024.1480847/fullSirtuin 1bone mineral densitybone turnover markerstype 2 diabetes mellitusbone metabolism |
| spellingShingle | Yao Xu Tianxiao Hu Peiwu Jiang Xiujing Wang Jiaqi Yao Huiling Shen Zhenying Zhang Bojing Zheng Ting Wang Yanxia Ren Jing Wang Qingying Tan Decreased sirtuin 1 in type 2 diabetes patients with abnormal BMD Frontiers in Endocrinology Sirtuin 1 bone mineral density bone turnover markers type 2 diabetes mellitus bone metabolism |
| title | Decreased sirtuin 1 in type 2 diabetes patients with abnormal BMD |
| title_full | Decreased sirtuin 1 in type 2 diabetes patients with abnormal BMD |
| title_fullStr | Decreased sirtuin 1 in type 2 diabetes patients with abnormal BMD |
| title_full_unstemmed | Decreased sirtuin 1 in type 2 diabetes patients with abnormal BMD |
| title_short | Decreased sirtuin 1 in type 2 diabetes patients with abnormal BMD |
| title_sort | decreased sirtuin 1 in type 2 diabetes patients with abnormal bmd |
| topic | Sirtuin 1 bone mineral density bone turnover markers type 2 diabetes mellitus bone metabolism |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2024.1480847/full |
| work_keys_str_mv | AT yaoxu decreasedsirtuin1intype2diabetespatientswithabnormalbmd AT tianxiaohu decreasedsirtuin1intype2diabetespatientswithabnormalbmd AT peiwujiang decreasedsirtuin1intype2diabetespatientswithabnormalbmd AT xiujingwang decreasedsirtuin1intype2diabetespatientswithabnormalbmd AT jiaqiyao decreasedsirtuin1intype2diabetespatientswithabnormalbmd AT huilingshen decreasedsirtuin1intype2diabetespatientswithabnormalbmd AT zhenyingzhang decreasedsirtuin1intype2diabetespatientswithabnormalbmd AT bojingzheng decreasedsirtuin1intype2diabetespatientswithabnormalbmd AT tingwang decreasedsirtuin1intype2diabetespatientswithabnormalbmd AT yanxiaren decreasedsirtuin1intype2diabetespatientswithabnormalbmd AT jingwang decreasedsirtuin1intype2diabetespatientswithabnormalbmd AT qingyingtan decreasedsirtuin1intype2diabetespatientswithabnormalbmd |